Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels

Table 1 Cohort demographics

	Knight ADRC	ADNI1	ADNI2	BIOCARD	HB	Mayo	Sweden	UPenn	UW
n = 3146	805	390	397	184	105	433	293	164	375
Age (years)	70.39 ± 9.12	77.89 ± 6.89	73.28 ± 7.47	62.10 ± 9.46	67.52 ± 9.24	78.73 ± 6.35	75.15 ± 7.63	71.60 ± 8.98	62.35 ± 16
Age range (years)	37–91	58–93	55–92	23–86	45–84	50–95	50–88	50–94	21–88
Male (%)	46.09	60	54.91	41.53	54.29	60.51	37.54	41.46	50.67
APOE ε4 positive (%)	40.75	50	38.29	34.43	54.29	27.5	76.11	55.56	43.28
CDR > 0 (%)	29.34	71.28	71.03	5.43	–	22.17	100	62.8	33.33
Aβ₄₂ levels^a	650.40 ± 305.59	169.83 ± 56.0	179.98 ± 51.31	386.90 ± 89.93	77.59 ± 23.30	331.0 ± 122.21	262.43 ± 72.77	163.55 ± 53.54	141.90 ± 41.42
p-tau₁₈₁ levels^a	64.94 ± 34.26	34.13 ± 18.52	38.63 ± 21.21	38.94 ± 12.30	–	23.16 ± 10.55	105.76 ± 41.82	36.96 ± 26.80	56.56 ± 29.32
tau levels^a	372.40 ± 235.41	97.26 ± 52.03	79.69 ± 47.79	66.56 ± 26.60	84.27 ± 36.79	104.29 ± 58.06	782.20 ± 301.68	93.66 ± 54.29	61.64 ± 42.77

^aReported as mean ± standard deviation in pg/mL
ADRC Alzheimer’s Disease Research Center, ADNI Alzheimer’s Disease Neuroimaging Initiative, APOE apolipoprotein E, BIOCARD Predictors of Cognitive Decline Among Normal Individuals, CDR Clinical Dementia Rating, HB Saarland University in Homburg/Saar, Germany, Mayo Mayo Clinic, Sweden Sahlgren’s University Hospital, Sweden, UPenn Perelman School of Medicine at the University of Pennsylvania, UW University of Washington